Psoriatic arthritis (PsA) is a serious and potentially disabling condition that affects about 30% of patients with psoriasis. The joint involvement of PsA often occurs about 10 years after the appearance of skin disease. In addition to the physical and functional impairments from joint destruction, PsA negatively impacts relationships, activities of daily living, work productivity, and overall quality of life (QoL).  Unfortunately, individuals with PsA are often undiagnosed or misdiagnosed. Dermatologists clearly have an important role in detecting early signs of PsA, and the overlapping treatment needs of patients often require collaborative care between dermatologists and rheumatologists.

This Psoriatic Arthritis Hub is dedicated to providing educational activities, resources, and tools to improve the care of patients with PsA.

Live Webcast: All Hands: Integrating a Teams Approach to Risk-Benefit Individualization of Rheumatoid Arthritis and Psoriatic Arthritis Therapy

Register Now

Wednesday, January 27, 2021 | 12:00 PM – 1:30 PM ET | Although rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with irreversible joint damage and physical disability, remission is now an achievable goal for the majority of patients, owing to advances in early diagnosis, new therapies, and improved treatment strategies. This CME Outfitters Live and OnDemand webcast focuses on integrating a multidisciplinary approach to treating PsA and RA through case-based learning, with expert faculty discussing management strategies and how to integrate shared decision-making (SDM) into practice to facilitate appropriate treatment selection and empower patients.

Hitting the Target with IL-23 Inhibitors in Psoriatic Arthritis

Participate Now

Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease with a significant impact on quality of life and functional ability. Despite the data showing the overall impact of PsA, delays in diagnosis are common, which can lead to long-term joint damage and functional disability. In this CME Outfitters Live and OnDemand activity, expert faculty will focus on assessment, treatment, and management strategies to provide patients with the best treatment aligned with evolving evidence and expert recommendations.

The Importance of Treating What Matters to the Patient – Impact of Psoriatic Arthritis Therapies on Patient-Reported Outcomes

Participate Now

In this CME Outfitters CME Snack, expert faculty focus on treat-to-target approaches and digital health tools. Treat-to-target approaches are important for proper treatment as without having targets as ways of measuring how a patient is doing, clinicians have no way of improving on care over time. Digital health tools help both the clinician and the patient by providing both treatment guidelines and the ability to monitor disease progression and medication adherence.  Note: Credit Is No Longer Available

Personalizing the Care of Patients with Psoriatic Arthritis – Factors Influencing Treatment Selection

Participate Now

Clinicians should be choosing agents based on what the phenotype of disease is, but with consideration to comorbidities. In this CME Outfitters CME Snack, expert faculty discuss and safety of agents used in treating PsA, taking patients’ comorbidities into account.  Note: Credit Is No Longer Available

Targeted Pathways in Psoriasis and Psoriatic Arthritis – Implications for Improved Patient Outcomes

Participate Now

Join CME Outfitters and our expert faculty in this CME Snack for a discussion about PsA treatment strategies and best implementation practices for current and emerging biologic treatment options with a focus on molecular targets.  Note: Credit Is No Longer Available

Practicing Precision Medicine in Psoriatic Arthritis: Strategies and Digital Health Tools for Managing a Chronic Disease

Participate Now

Several agents have been FDA-approved for the treatment of moderate-to-severe PsA since 2008, and there are still more currently under investigation. In this CME Outfitters Live and On Demand expert faculty will highlight the molecular targets of currently available and emerging biologic treatments for managing PsA, discuss individualized treatment plans, and provide updates on the latest clinical trials focused on the impact of long-term treatment, improving pain, and quality of life.  Note: Credit Is No Longer Available

SMART Goals for Psoriatic Arthritis

Free 1-on-1 Digital Health Coaching for Your Patients

Enroll your patients in this fully funded digital health coaching program. Over the course of 3 months, Pack Health Advisors provide behavior change support by:

• Creating personalized action plans to change health behaviors

• Providing tangible accountability tools (e.g. medication charts, health budgets, and day trackers)

• Referring to local resources (e.g. transportation resources)

• Arranging for services (e.g. mail-order pharmacy)

• Securing discounts/cost savings (e.g. medication assistance programs)


It’s easy to claim your FREE Pack Health Digital Advisor kit:

Step 1: Visit and click “Get Started”.

Step 2: Enter your patients’ information

FAQ for Clinicians | PSA Program Overview | 60-Second Fax Enrollment Form

Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. 2017;47:351-360. (PDF)


Zhang A, Kurtzman DJB, Perez-Chada LM, Merola JF. Psoriatic arthritis and the dermatologist: an approach to screening and clinical evaluation. Clin Dermatol.2018;36:551-560. (LINK)


Elalouf O, Chandran V. Novel therapeutics in psoriatic arthritis: what is in the pipeline? Curr Rheumatol Rep.2018;20:36. (LINK)


Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open.2018;4:e000656. (PDF)


Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol.2016;12:743-750. (PDF)


Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol.2016;68:1060-1071. (PDF)


Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis.2016;75:499-510. (PDF)